FDAnews
www.fdanews.com/articles/197069-nih-to-test-remdesivir-with-eli-lillys-olumiant-for-covid-19
NIH-pic.jpg

NIH to Test Remdesivir with Eli Lilly’s Olumiant for COVID-19

May 12, 2020

The National Institutes of Health is sponsoring a clinical trial of Gilead Sciences’ antiviral remdesivir combined with Eli Lilly’s anti-inflammatory Olumiant (baricitinib) for treatment of COVID-19 infections.

The trial is the next step in the adaptive COVID-19 treatment trial that reported positive results from remdesivir treatment alone. The new trial will evaluate whether adding baricitinib shortens the recovery time.

Investigators expect to enroll approximately 1,000 patients at 100 sites in the U.S. and around the world.

View today's stories